Concepedia

Evaluation of the Effects of Acarbose on Weight and Metabolic, Inflammatory, and Cardiovascular Markers in Patients with Obesity and Overweight

Noushin Khalili, Alireza Safavipour

International Journal of Preventive Medicine · 2020 · 15 citations · 11 references

DOIFull text

Open access

Abstract

The administration of acarbose in patients with MetS can decrease weight and abdominal obesity as well as the reduction of inflammatory and cardiovascular markers, including CRP, EFT, and IMT and also increases HDL.

References

11

American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease

Paul S. Jellinger, Yehuda Handelsman, Paul D. Rosenblit et al. · Endocrine Practice · 2017 · 1.1K citations

, , +7

Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue

Nathalie Esser, Laurent L’homme, Arnaud De Roover et al. · Diabetologia · 2013 · 233 citations · Full text

, , +13

Hyperglycemia-Induced Thrombin Formation in Diabetes: The Possible Role of Oxidative Stress

Antonio Ceriello, Roberta Giacomello, Giuliana Stel et al. · Diabetes · 1995 · 180 citations

Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients

Stephen J. Nicholls, E. Murat Tuzcu, Kathy Wolski et al. · Journal of the American College of Cardiology · 2011 · 114 citations

, , +10

Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load

Giuseppe Derosa, Pamela Maffioli, Ilaria Ferrari et al. · European Journal of Pharmacology · 2010 · 53 citations

, , +10